News

From 16 to 18 June 2022, Warsaw

Carvolix will attend to the 2022 ISMICS Congress

May 10 & 11, 2022

Speakers: Michel Finance, President and François Laborde Chief Medical Officer

On April 27, 2022 at 3:25 pm

Speakers: Michel Finance, President and François Laborde Chief Medical Officer

Carvolix today announced the appointment of Soad El Ghazouani as a new independent board member to the Carvolix Board of Directors.

Soad El Ghazouani has over 25 years of global experience in the medical device industry with extensive knowledge of the pan-European and North American markets.

Carvolix today announces the success of the first ever Kalios^TM mitral ring adjustment on a patient suffering from post-operative recurrence of severe mitral insufficiency.

Prof. Alberto Albertini (GMV Maria Cecilia Hospital de Cotignola, Italy) successfully performed the percutaneous adjustment of the original Kalios^TM annuloplasty ring 11 months after its implantation following a recurrence of severe mitral insufficiency.

Carvolix launches its IPO on the regulated Euronext Paris market

• Capital increase of approximately €33.0 million, which may be increased to approximately €43.6 million in the event of the full exercise of the extension and over-allotment clause

• Subscription commitments received in the amount of €20 million

• Indicative price range applicable to the Offering: between €7.40 and €9.80 per share

• Subscription period: from 27 May 2021 to 8 June 2021, inclusive, for the French Public Offer (5:00 p.m. for subscriptions over the counter and 8:00 p.m. for internet subscriptions) and until noon on 9 June 2021 for the international offering